94 F. Supp. 3d 481
S.D.N.Y.2015Background
- Plaintiff S.M., covered by an Oxford ERISA-governed health plan, was treated for non-Hodgkin’s lymphoma and received Gamunex (IVIG) after severe pneumonia in 2011; Oxford initially approved three months but later denied continued coverage for lack of evidence of impaired antibody production and unresolved condition.
- Oxford’s Plan grants the administrator discretionary authority to determine medical necessity and has an IVIG-specific coverage policy that requires documentation of impaired humoral immunity, response to therapy, and recurrent infections for continuation.
- Oxford requested additional clinical information twice; Dr. Cuttner (treating oncologist) submitted records and letters but did not document antibody response to vaccine challenge or a clear history of recurrent severe infections.
- Internal denial/appeal process: initial determinations by Oxford medical directors (Dr. Lundblad), internal appeal by Dr. Bahr, and an external independent review (MCMC) by a hematology/internal-medicine physician, all of which upheld the denial.
- Plaintiff sued under ERISA § 502(a)(1)(B) (benefits) and § 502(c) (penalties), and arguably § 502(a)(3) (fiduciary relief); cross-motions for summary judgment were filed. The district court denied plaintiff’s motion, granted defendants’ motion, dismissed non-Oxford corporate defendants, and denied severance and penalty claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standard of review (discretion) | Plan discretion is limited; but plaintiff argued conflict warrants de novo | Oxford: plan reserves discretion; arbitrary-and-capricious applies | Arbitrary-and-capricious applies (parties agreed); no basis to upgrade to de novo based on conflict |
| Whether Oxford’s denial was arbitrary and capricious | Denial was unreasonable, tainted by conflict, reviewer unqualified, and ignored Rituxan/chemotherapy context | Denial supported by substantial evidence: missing documentation re: impaired antibody responses and recurrent severe infections | Denial was supported by substantial evidence and not arbitrary or capricious — summary judgment for defendants |
| Conflict of interest / extra-record evidence | Structural and case-specific conflicts (insurer pays claims) and procedural irregularities justify weighing conflict heavily and admitting extra-record evidence (e.g., deposition, Rituxan docs, 2013 IAR) | Oxford had procedural safeguards, separate reviewers, and no evidence conflict affected outcome; no good cause to expand record | Court weighed conflict but found safeguards and no evidence it tainted decision; refused to expand administrative record for substantive review |
| Breach of fiduciary / fraudulent concealment / severance request | Oxford (and employees) omitted/misrepresented materials to external reviewer, failed fair process; seek severance and jury trial on fraud-related claims | Claims are preempted by ERISA as they seek to challenge plan benefit determination; plaintiff failed to plead fraud with particularity and cannot show detrimental reliance or appropriate equitable relief | Fraudulent-concealment/severance denied; breach-of-fiduciary allegations dismissed as unsupported and largely preempted; no injunctive or disgorgement relief granted |
Key Cases Cited
- Firestone Tire & Rubber Co. v. Bruch, 489 U.S. 101 (standard for ERISA review: de novo unless plan grants discretion)
- Metro. Life Ins. Co. v. Glenn, 554 U.S. 105 (conflict of interest as a factor under arbitrary-and-capricious review)
- Fay v. Oxford Health Plan, 287 F.3d 96 (2d Cir. case applying arbitrary-and-capricious review to Oxford denial)
- Krauss v. Oxford Health Plans, Inc., 517 F.3d 614 (2d Cir. guidance on expanding administrative record; good cause required)
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment standard)
- Nechis v. Oxford Health Plans, Inc., 421 F.3d 96 (limits on equitable relief and disgorgement under ERISA § 1132(a)(3))
- Hardt v. Reliance Standard Life Ins. Co., 560 U.S. 242 (attorney’s-fee entitlement requires some success on the merits)